Effectiveness of rivastigmine in Alzheimer's disease. Participation in trials should be based on clinical uncertainty, not enforcement
- PMID: 10678874
- PMCID: PMC1127540
Effectiveness of rivastigmine in Alzheimer's disease. Participation in trials should be based on clinical uncertainty, not enforcement
Comment on
-
New drug treatment for Alzheimer's disease: lessons for healthcare policy.BMJ. 1998 Mar 7;316(7133):762-4. doi: 10.1136/bmj.316.7133.762. BMJ. 1998. PMID: 9529416 Free PMC article. Review. No abstract available.
-
Effectiveness of rivastigmine in Alzheimer's disease. Improvements in functional ability remain unestablished.BMJ. 1999 Sep 4;319(7210):640-1. doi: 10.1136/bmj.319.7210.640a. BMJ. 1999. PMID: 10473490 Free PMC article. No abstract available.
References
-
- Collins R, Doll R, Peto R. Ethics of clinical trials. In: Williams CJ, editor. Introducing new treatments for cancer: practical, ethical and legal problems. New York: John Wiley; 1992. pp. 49–65.
-
- Bucks RS, Ashworth DL, Wilcock GK, Siegfried K. Assessment of activities of daily living in dementia: development of the Bristol activities of daily living scale. Age Ageing. 1996;25:113–120. - PubMed
-
- Stern Y, Albert A, Sano M. Assessing patient dependence in Alzheimer's disease. J Gerontol. 1994;49:M216–M222. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical